Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Weitz, Ilene
APPELHUS, NCT04889430 / 2020-005186-13: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy	Recruiting	3	50	Europe, Japan, US, RoW	Iptacopan, LNP023	Novartis Pharmaceuticals, Novartis Pharma AG	Atypical Hemolytic Uremic Syndrome	09/28	03/29
NCT04747613: Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria	Active, not recruiting	3	208	Europe, Japan, US, RoW	Iptacopan, LNP023	Novartis Pharmaceuticals	Paroxysmal Nocturnal Hemoglobinuria	10/27	10/27
Trey, Hannah
APPELHUS, NCT04889430 / 2020-005186-13: Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy	Recruiting	3	50	Europe, Japan, US, RoW	Iptacopan, LNP023	Novartis Pharmaceuticals, Novartis Pharma AG	Atypical Hemolytic Uremic Syndrome	09/28	03/29